A new study has found that a three-dose regimen of the hepatitis B vaccine is effective in protecting people with HIV from the virus. The study, which was conducted by researchers at the University of California, San Francisco, and published in the journal Clinical Infectious Diseases, looked at data from nearly 1,400 people with HIV who were vaccinated against hepatitis B between 2006 and 2014.
Of those who received all three doses of the vaccine, 97 percent were protected against the virus after one year. The protection lasted for at least four years in most cases, and in some people it was still present after eight years. In contrast, only 78 percent of people who received two doses of the vaccine were protected against the virus after one year.
People with HIV are at an increased risk of developing hepatitis B, and the virus can cause serious health problems, including liver cirrhosis and liver cancer. The hepatitis B vaccine is currently recommended for all people with HIV, regardless of whether they have already been infected with the virus.
The new study provides strong evidence that the vaccine is effective in protecting people with HIV, and that a three-dose regimen is superior to a two-dose regimen. The findings could have important implications for public health, as they suggest that increasing the number of doses of the hepatitis B vaccine could help to further reduce the burden of the virus among people with HIV.
Three-dose hepatitis B vaccine regimen protects people with HIV
According to a new study, a three-dose regimen of the hepatitis B vaccine is as effective in protecting people with HIV as it is in the general population.
The study, published in The Lancet Infectious Diseases, compared the rates of hepatitis B virus (HBV) infection in people with HIV who received either the standard three-dose HBV vaccine or an experimental two-dose regimen.
After one year, the rate of HBV infection was similar in both groups, at less than 1%.
“This is the first study to show that the hepatitis B vaccine is equally effective in people living with HIV as it is in the general population,” said study author Dr. Salvatore Aloi of the National Institute for Infectious Diseases in Rome.
The findings are important because people with HIV are at an increased risk of HBV infection.
“The hepatitis B virus is a serious threat to people living with HIV,” said Aloi. “This study provides strong evidence that the vaccine is an effective way to prevent HBV infection in this population.”
The hepatitis B vaccine is recommended for all adults, including those with HIV. The standard three-dose regimen is given over a six-month period.